Pulike Biological Engineering, Inc. (SHA:603566)
10.28
+0.01 (0.10%)
Oct 14, 2026, 11:29 AM CST
SHA:603566 Revenue
Pulike Biological Engineering had revenue of 242.03M CNY in the quarter ending June 30, 2026, a decrease of -13.81%. This brings the company's revenue in the last twelve months to 1.02B, down -8.68% year-over-year. In the year 2025, Pulike Biological Engineering had annual revenue of 1.09B with 4.54% growth. That makes Pulike Biological Engineering the 19,438th largest company in the world by revenue and 3,549th in China.
Revenue (ttm)
1.02B
Revenue Growth
-8.68%
P/S Ratio
3.44
Revenue / Employee
672.63K
Employees
1,519
Market Cap
3.51B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.09B | 47.32M | 4.54% |
| Dec 31, 2024 | 1.04B | -210.13M | -16.77% |
| Dec 31, 2023 | 1.25B | 22.62M | 1.84% |
| Dec 31, 2022 | 1.23B | 131.50M | 11.97% |
| Dec 31, 2021 | 1.10B | 170.06M | 18.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hefei Lifeon Pharmaceutical | 1.51B |
| Xiangxue Pharmaceutical | 1.48B |
| Qingdao Vland Biotech INC. | 1.42B |
| Landfar Bio-medicine | 660.26M |
| Lifecome Biochemistry | 470.43M |
| Assure Tech (Hangzhou) | 410.36M |
| Beijing Scitop Bio-tech | 372.08M |
| Jiangsu Bioperfectus Technologies | 310.89M |